Latest Biologic Stories
-- Major European markets can finally benefit from the availability of Inflectra following the patent expiry of reference product Remicade® (infliximab) LAKE FOREST, Ill., Feb.
SAN DIEGO, Feb. 13, 2015 /PRNewswire/ -- Pfenex Inc.
MUMBAI, February 12, 2015 /PRNewswire/ -- Date Info: 10 Mar 2015 to 11 Mar 2015 Venue Info: The Kensington Close Hotel, Wrights Lane, London, UK
CRANBURY, N.J., Feb.
LONDON, February 11, 2015 /PRNewswire/ -- Report Details Biosimilar therapeutic antibodies - see why originator companies should now fear those competitors,
Provides additional details on AT-001 pivotal efficacy study, announces two technical section complete letters for safety, provides manufacturing update for AT-004, and announces completion of enrollment
SAN DIEGO and LAKE FOREST, Ill., Feb. 10, 2015 /PRNewswire/ -- Pfenex Inc.
BCC Research (http://www.bccresearch.com) reveals in its new report on biologic therapeutic drugs; the biologics or biopharmaceutical therapeutic
Primary Efficacy Analysis Demonstrates Clinical Equivalence THOUSAND OAKS, Calif., Feb.
-- CEO to Participate on "Trust Your Gut" - Therapeutic Opportunities from the Microbiome Panel -- ROCKVILLE, Md., Feb. 3, 2015 /PRNewswire/ -- Synthetic Biologics, Inc.
- A serpent whose bite was fabled to produce intense thirst.